Last reviewed · How we verify
Allergovit
At a glance
| Generic name | Allergovit |
|---|---|
| Also known as | Allergovit, grass pollen 100%, Allergopharma, Germany |
| Sponsor | University of Zurich |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants
- Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials (PHASE2)
- Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? (PHASE4)
- Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens (PHASE3)
- Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis (PHASE3)
- Mechanisms of Allergen Immunotherapy (NA)
- Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy (PHASE4)
- Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allergovit CI brief — competitive landscape report
- Allergovit updates RSS · CI watch RSS
- University of Zurich portfolio CI